GPs debate new diabetes drugs

In a submission to the government’s review of type 2 diabetes medicines, the RACGP said the greatest burden of disease was cardiovascular death and microvascular complications including eye, neurological and renal disease.

Dr Gary Deed, chair of the RACGP National Faculty of Special Interests Diabetes Network said although the introduction of novel anti-hyperglycaemic agents had attempted to address this burden of disease, there was no conclusive outcome.